• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nutriband Inc WT (NQ: NTRBW )

    1.270 +0.100 (+8.55%)
    Streaming Delayed Price Updated: 12:12 PM EDT, Sep 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 744
    Open 1.270
    Bid (Size) 0.6500 (10)
    Ask (Size) 1.800 (10)
    Prev. Close 1.170
    Today's Range 1.270 - 1.270
    52wk Range 0.1885 - 3.440
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Nutriband Inc. Authorizes $1M Share Buyback Program
    Via ACCESSWIRE
    Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
    Via ACCESSWIRE

    Performance

    YTD
    +323.47%
    +323.47%
    1 Month
    +3.25%
    +3.25%
    3 Month
    +23.30%
    +23.30%
    6 Month
    +351.96%
    +351.96%
    1 Year
    +118.97%
    +118.97%

    More News

    Read More
    Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
    Via ACCESSWIRE
    Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
    Via ACCESSWIRE
    Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
    Via ACCESSWIRE
    Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
    Via ACCESSWIRE
    Nutriband Inc. Announces $8.4M Private Placement
    Via ACCESSWIRE
    Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
    Via ACCESSWIRE
    Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
    Via ACCESSWIRE
    Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
    Via ACCESSWIRE
    Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
    Via ACCESSWIRE
    Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
    Via ACCESSWIRE
    Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
    Via ACCESSWIRE
    Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
    Via ACCESSWIRE
    Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
    Via ACCESSWIRE
    Nutriband CEO Publishes Letter to Shareholders
    Via ACCESSWIRE
    Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
    Via ACCESSWIRE
    Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
    Via ACCESSWIRE
    Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
    Via ACCESSWIRE
    Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
    Via ACCESSWIRE
    Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications
    Via Get News
    Topics Intellectual Property
    Exposures Intellectual Property
    Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
    Via TheNewswire.com
    Topics Intellectual Property
    Exposures Intellectual Property
    Nutriband Unveils Groundbreaking Innovation in Transdermal Medications
    Via News Direct
    Topics Intellectual Property
    Exposures Intellectual Property
    Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
    Via FinancialNewsMedia
    Topics Death Intellectual Property
    Exposures Death Intellectual Property
    Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology
    Via FinancialNewsMedia
    Topics Intellectual Property
    Exposures Intellectual Property
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.